Cardiovascular risk tables

Estimating risk is not the problem, using it to tailor treatment to individuals is.

In the linked study, Hippisley-Cox and colleagues develop and validate the second version of the QRISK cardiovascular disease risk algorithm (QRISK2), an attempt to more accurately estimate cardiovascular risk in patients from different ethnic groups in England and Wales.1

The advent of the first Framingham risk tables in the early 1960s was a challenge for most doctors. Since the second world war the management of cardiovascular risk has been part of the core business of general practice, but the single risk model dominated. Hypertension, diabetes, and hypercholesterolaemia were islands, each with its own experts fighting for bigger kingdoms by pushing for ever stricter boundaries and demanding more attention.

Framingham taught us to look at the different risk factors, and provided a major lesson: a cumulative average risk could be more important than one peak. Yet soon the extrapolation of these US tables to European populations seemed to overshoot the real risk in these groups.2 3 The SCORE tables used the same risk factors to calculate corrected European cardiovascular mortality.4

More recently the ASSIGN5 and now the QRISK tables tried to incorporate some other known risk factors, especially deprivation and family history. Again, a major step: for several decades the medical community has had to face the troubling fact that cardiovascular morbidity and mortality are strongly and independently related to deprivation.6 7 If we ignore this we overestimate the risk for rich people (and overlook them) and underestimate that for poor people. It’s probably naive to think that we can close the gap in cardiovascular risk just by giving more statins to poor people.

If epidemiologists could estimate cardiovascular risk accurately, would it solve our problems in managing patients? Not at all. Risk calculation itself is based on evidence. However, using risk calculation in managing patient relies on consensus. When does a “risk” become a “high risk”? At what moment does a high risk justify starting lifelong drug treatment? The SCORE tables are useful, but when the European Guidelines tried to implement these tables and defined a 5% risk of death within the coming 10 years as high risk (comparable to a 20% risk in the Framingham tables),8 it led to an enormous medicalisation of many healthy elderly people, as proved by the Nordic Risk Group.9 Nearly all Norwegian men aged 60 years and older and all women aged 65 years and older were classified as at “high risk”—in a population with one of the highest life expectancies in the world.

To use an absolute risk score as a threshold for starting drugs is dangerous and not evidence based. It is therefore surprising that the recent NICE guidelines strongly recommend statins for anyone with a cardiovascular risk score of 20 or more in the Framingham tables.10

Age is such an important risk factor for developing cardiovascular problems within the next 10 years that all risk tables are misleading. Becoming older is by far the strongest predictor for morbidity and mortality—this is a biological fact. By looking at the risk tables, anyone can see what happens: by age 65, a large group has reached the 20% risk threshold, and lipid lowering drugs are prescribed for the rest of their lives.

A non-smoking man of 70 with a systolic blood pressure of 130 mm Hg and a total cholesterol concentration of 5 mmol (far below the median cholesterol concentration in most European countries) is at high risk according to the SCORE criteria. Unfortunately, most of the trials of statins include only a few people older than 70.11 The PROSPER trial, which specifically looked at this elderly population, showed that the primary composite endpoint (cardiovascular death or non-fatal infarction or cerebrovascular accident) was lowered by only 13% (48 people have to be given statins for three years to prevent one event), a marginally significant gain for cardiovascular death (relative risk 0.76, 95% confidence interval 0.58 to 0.99; NNT 112 for three years) and no effect at all on total mortality.12 In contrast, a male smoker aged 50 with a systolic blood pressure of 145 mm Hg and a total cholesterol of 6.5 mmol/l is at low risk on SCORE.

A better way of using risk tables would be to compare the risk of an individual with the minimal risk of people of the same sex and age. Treatment should be considered when he or she has, for example, three times that minimal risk for his or her age and sex. This will prevent overtreatment of elderly people whose high risk is related to age and undertreatment of younger people who are at high risk. For our two examples the treatment options would be totally different.

All attempts to make risk tables more accurate, as done by Hippisley-Cox and colleagues in the QRISK2 algorithm,13 are necessary and should be welcomed. However, this is not the key problem. We have to fundamentally rethink how to use risk tables when making treatment decisions in practice, taking into consideration the medicalisation of healthy older people and the correct use of drugs.
Measuring deaths from conflict
New method is promising but is still likely to underestimate deaths

In the linked study, Obermeyer and colleagues challenge conventional thinking about deaths related to war and force us to re-evaluate some well established assumptions about these deaths. Deaths in combatants and non-combatants are always underestimated during conflicts between armed groups in poor countries that are not national armies. Even in middle income developing countries, counts that are purported to be precise fail to include most of those killed.

Obermeyer and colleagues used demographic data from world health surveys collected before and after conflicts in 13 countries over the past 50 years. The surveys collect information from one respondent for each household about sibling deaths, including whether the deaths were related to war. The data are then compared with those obtained through passive reports (mainly from eyewitnesses and the media). This method eliminates some of the ambiguity rampant in this highly politicised field.

Obermeyer and colleagues estimate that 5.4 million (95% confidence interval 3.0 to 8.7) deaths occurred as a result of war in 13 countries from 1955 to 2002; the numbers ranged from 7000 in the Republic of Congo to 3.8 million in Vietnam. The estimates were about three times higher than those obtained from passive reports.

Limitations of the analysis include the relatively small number of surveys analysed (13) and the fact that five of them were based on relatively small national samples. Also, because undercounting varies greatly between conflicts, the confidence intervals are wide. The pattern of undercounting was not consistent—some countries even overcounted the number of deaths.

Good quality data on the epidemiology of violence often become available only years after the killing has ended. Real time surveillance systems that can count most deaths as they occur are needed to solve this problem. In poor and unstable countries, where almost all wars now occur, such systems are rare.

Despite rigorous efforts to correct for under-reporting, Obermeyer and colleagues could not correct for household members who chose not to report deaths. How the relevant questions were asked in face to face interviews can greatly influence the results obtained. Similarly, the total number of deaths in war may be grossly underestimated by multiyear demographic modelling. Half a million deaths can occur unnoticed when demographic models do not count actual deaths but depend on projections from count data that are decades old.

Finally, the study only includes violent deaths. In the poorest countries, where most conflicts now occur, a rise in deaths from infectious diseases often dwarfs the number of violent deaths during a conflict. For all these reasons, Obermeyer and colleagues’ study is likely to underestimate the importance of conflict as a cause of death.

To reduce casualties from violence or disease we need current data, as well as assessments of their inadequacies. A lack of such assessments has fuelled controversies over estimates of deaths in non-combatants that are based on data from field epidemiological studies in Iraq, Darfur Sudan, and the Democratic Republic of Congo. But we should not despair. A generation ago little controversy existed over such figures because epidemiological studies like these did not even exist.

The news about war related deaths in the world these days is both good and bad. The good news is that fewer combatants die today than at any time in the past 100 years, and the number and intensity of military conflicts have declined considerably since 1994. The bad news is that most excess deaths in

References


Richard Garfield

Bendixen professor of clinical international nursing, School of Nursing, Columbia University, Box 6, New York City, NY 10032, USA

Competing interests: None declared.

Provenance and peer review: Commissioned; not externally peer reviewed.

BMJ 2008;336:1446-7
doi: 10.1136/bmj.a146
Seroprotection against serogroup C meningococcal disease

Is higher if vaccination is given in the second decade of life rather than in the first

**Neisseria meningitidis** is a leading cause of bacterial meningitis worldwide. Most cases in developed countries are caused by endemic disease. The incidence is around 1-2 per 100,000,\(^1\)\(^2\) with rates among infants as high as 20 per 100,000.\(^2\) Children younger than 2 years have the highest incidence of meningococcal disease, with a second peak between 15 and 24 years. Most cases are caused by serogroups A, B, C, W-135, and Y. Serogroups C and B predominate in temperate countries.\(^1\)\(^3\)

In the accompanying study, Snape and colleagues evaluate the persistence of serum bactericidal antibody against meningococcal serogroup C in a large cohort of adolescents originally immunised with serogroup C meningococcal conjugate vaccines at 6-15 years of age.\(^8\) These vaccines, now used in many countries, were licensed on the basis of immunogenicity rather than clinical efficacy.\(^5\) Despite the high public profile of meningococcal disease, it is relatively rare, which makes traditional efficacy studies prohibitive and impractical. The approach to licensing this vaccine was therefore novel and was based on its ability to induce serum bactericidal antibody at titres known to correlate with clinical protection. Since the licence was granted, effectiveness studies have confirmed the validity of this approach and have allowed further fine tuning of these serological correlates of protection.\(^5\)\(^8\)

A systematic review conducted in 2006 confirmed that serogroup C meningococcal conjugate vaccines are highly immunogenic in all age groups.\(^5\) However, a decline in serological protection over time was noted in children who were vaccinated in infancy, a phenomenon also seen with the *Haemophilus influenzae* type b conjugate vaccines. The relevance of this finding was not clear, as the presence of immunological memory implied that a rapid immune response should occur when antigen was encountered. This might result in clinical protection, even in the absence of detectable circulating antibody. But meningococcal disease has a short incubation period, so the speed of response is crucial. Subsequent observations on vaccine failures and analysis of vaccine effectiveness (for both the meningococcal and influenza vaccines) now support the need for persistence of bactericidal antibody.\(^10\)

In the United Kingdom, the public health response to this has been the recent addition of a booster dose of these vaccines in the second year of life.

Snape and colleagues found that five years after immunisation, 84.1% (95% confidence interval 81.6 to 86.3) of 987 participants had bactericidal antibody titres ≥1:8. However, geometric mean titres were significantly lower in 11-13 year olds (147; 115 to 188) than in 14-16 year olds (300; 237 to 380) and 17-20 year olds (361; 253 to 513) (P<0.0001 for both comparisons). Protective titres were achieved in around 10% fewer of the 11-13 year olds than in the older groups. The authors conclude that antibody titres five years after immunisation are higher if children are vaccinated in the second decade of life rather than the first.\(^4\)

These data emphasise the importance of age at vaccination for conjugate vaccines with regard to protection and persistence, and they have implications for the number of vaccine doses needed at different ages. The increased immune response seen in the second decade of life is difficult to explain. The authors suggest that the older participants may have had more natural exposure to serogroup C meningococci just before or after they were immunised and so were better primed (or boosted) by carriage, with better primary responses and better persistence. In the era before vaccination, carriage was highest in the adolescent age group (albeit only at around 0.5%).\(^11\)

Study participants over the age of 15 were therefore vaccinated around the time of maximum carriage and exposure. Seroprevalence studies of group C (pre-vaccine) and group B meningococci also show sharp increases in antibody titres in adolescent age groups, which lends support to this argument.

---

The authors’ second hypothesis is that immune responses mature in the second decade of life, so that primary and persistent vaccine responses are enhanced. They found no literature to support this with respect to conjugate vaccines, but it may be possible to test this hypothesis in the next phase of the UK meningococcal vaccine programme. The meningococcal vaccination programme has been a great success—high levels of direct and indirect vaccine protection have been recorded; carriage and invasive disease have declined significantly 2,3; for the first time ever, no one under 19 years old has died of this disease in the past year; and the feared replacement by serogroup B disease has not occurred. This experience may help other countries to define the best strategy to prevent serogroup C disease, taking into account their own epidemiological reality. However, concerns about ongoing control of disease as children in certain age groups get older and perhaps lose their antibodies— as shown by Snape and colleagues 4—remind us that continued high quality surveillance must continue, even long after disease seems to have been controlled. 1

care and training from quality improvement experts in how to apply the “plan-do-study-act” quality improvement paradigm to surgical care. After the initial meeting, each hospital presented their progress, achievements, and lessons learnt. How to apply these lessons at home was then discussed.

At the end of the 18 month project we had made dramatic improvements in several key process of care measures, but little headway in others, and our postoperative infection rate had not improved. Some hospitals across the collaborative struggled to make even small improvements, whereas others described impressive gains and substantial reductions in infection.

Unfortunately, neither the quality improvement collaborative for surgical infection prevention nor hundreds of others that have been carried out over the past two decades are included in the systematic review by Schouten and colleagues. This cannot be blamed on the authors, who scanned more than 1000 journal abstracts to find 175 articles worth reviewing in detail. Of the 72 published studies that reported on the outcomes or effectiveness of a quality improvement collaborative, 60 (82%) used an uncontrolled study design, generally relying on a simple before and after approach that could not account for secular trends; relied on self report rather than third party chart review; and suffered from generally poor quality data management procedures. The remaining 12 reports represented nine studies, including two randomised controlled trials; seven showed at least some positive effects on process or outcome measures, while two were entirely negative. Even in this highly restricted group, most studies had methodological weaknesses that would be considered problematic outside of the field of quality improvement research. Of the two randomised controlled trials, one showed no benefit, whereas the other showed improvement in two process of care measures but not in outcomes.

Although the review is original it does have several important limitations. Firstly, it is debatable whether the nine studies included represent the global experience with quality improvement collaboratives, and thus whether the findings can be extrapolated to future collaboratives. Secondly, the small number of high quality studies makes it impossible to evaluate which characteristics of these collaboratives are associated with success. For example, the kinds of clinical conditions that are most suited to the approach, the attributes of a successful faculty, the ideal mix of team members, the number of sessions needed and how they should be structured, and the time period over which the quality improvement collaborative should take place.5

The third concern is whether aggregating the findings of a heterogeneous group of studies on quality improvement collaboratives makes much sense. To state that quality improvement collaboratives are modestly beneficial seems analogous to saying that, in general terms, drugs have beneficial effects on disease. Although this may be true, it hides the fact that some drugs improve outcomes for patients with certain conditions (for example, aspirin for secondary prevention of coronary artery disease) more than they do for others (for example, cholinesterase inhibitors for Alzheimer’s dementia).

A more fundamental question is whether the methods used in traditional biomedical research are sufficient to evaluate quality improvement collaboratives. Undoubtedly, randomised controlled trials are the optimal approach to test the efficacy of drugs. But, unlike most pharmacological trials in which a study coordinator ensures that patients are treated according to a strict protocol, this is not usually the case for quality improvement initiatives, which take place in a less controlled environment. Research into quality improvement that reports only the mean improvement in participants and controls misses an opportunity to explore important contextual factors that might have explained why two hospitals can have such different experiences when participating in the same quality improvement collaborative.

Future research should focus on the behaviours and actions of the participants themselves, such as how the executive sponsors tried to ensure that the team was successful, what role the doctor and nurse champions played in winning the support of their colleagues, and how information technology was used for the benefit of the project.7 8 While lip service has been paid to the need for these kinds of studies, they remain few and far between.9-11

1 Schouten LMT, Hulscher MEIL, van Everdingen IE, Huismans R, Grol RPTM. Evidence for the impact of quality improvement collaboratives: systematic review. BMJ 2008; doi: 10.1136/bmj.39750.749884.BE.
8 Mittman BS. Creating the evidence base for quality improvement collaboratives [see comment]. Ann Intern Med 2004;140:897-901.
Continuous publication
The next logical step

The BMJ is about to undergo another shift in the way that it publishes its content, which we hope will provide benefits for both readers and authors. From the beginning of July we will be publishing content continuously on bmj.com. All our articles will be published online as they become ready, so bmj.com will update several times a day. Once published, articles will then be selected for a subsequent print issue.

Why are we doing this? It’s a logical extension of what we’ve been doing for some time with online first publication of research, and it will give all articles the benefit of faster publication.1 This makes most sense in the context of research, news, and other topical items, but all authors appreciate seeing their work published as soon as possible.

Continuous publication also gives readers more flexibility in the way they engage with our content: as a continuous stream or in a weekly “package,” or both. And it will allow us to tailor the print journal—which is read largely by UK readers—to their needs.

The BMJ is the first major medical journal to move to continuous publication, but within publishing generally it is not alone. Broadcasters have long been posting news continuously on their websites, and many newspapers now post their articles online as soon as they are written, in advance of the next morning’s paper edition. People’s online behaviour suggests that their interest is primarily in individual articles and not in the print issues, or indeed even the journal in which they appear. The BMJ has for some years been taking full advantage of the web, giving authors all the space they need for their research papers and providing shorter versions in print. With the shift to continuous publication for all our content, we will carry an increasing amount of content that is online only, allowing us to serve our growing audiences around the world with content that is most relevant to their specific interests and needs.

The move creates various routes into our content for print and online readers. Print readers will have readable, relevant, clustered content presented to them in a preselected weekly package, with the possibility, as now, to go deeper into that content and to respond to it on bmj.com. For readers who like to use the print issue to find content on bmj.com, the current print issue will still be displayed on the home page, and previous print issues can be browsed in the archive. And PDFs of print issues can be printed off, in section-sized chunks.

Online users can browse current content via a rolling table of contents of all articles published in the past seven days. This will still be organised by section (editorials, news, research, etc).

An important aspect of the change is in the way that articles will be organised and cited. The online “publish ahead of print” model that we have been using for research articles assumed that they would eventually be published in a print issue, and the ultimate citation for that article derived from that print issue. Thus, when it was first published, an online first article had a year and a doi (a unique identifier for a digital object)—for example, BMJ 2008;336:123-5.

From now on, each article will have only one, permanent, citation and it will no longer derive from print. The citation will be year, volume, e-locator (a unique identifier for that article)—for example, BMJ 2008;337:a145—and this is what will appear in Medline, PubMed, and other bibliographical indexes. We will print this citation on every item we publish, in print and online, and authors will need to use it when they cite these BMJ articles.

Highwire Press, who provide our web platform and have built the tools that enable us to publish continuously, predict that in a few years’ time “everyone will be doing it.” We hope that our authors and readers will see the benefits, and as always we welcome your feedback.

1 Delamothe T. Is that it? How online articles have changed over the past five years. BMJ 2002;325:1475-8.